quality of life after cancer treatment (in all age groups) will in the future not only represent a social but also an economic consideration.
Introduction
Thanks to advances in the treatment of cancer in children and adolescents over the past decades, survival rates have today risen to 80% [1] . Based on the data of the German Childhood Cancer Registry (GCCR), about 33,000 surviving former cancer patients are included in their active long-term follow-up [2] . An overview of other figures pertaining to long-term childhood cancer survivors in Europe was provided by Winther et al. [3] . The underlying malignancy and its multifaceted treatment can not only induce transient somatic and psychological stress, but also long-term secondary diseases/late effects [4] .
Late effects may persist following acute episodes during treatment or develop early within the first 5 years, but they may also develop decades later. The presentation of late complications is associated with core cancer conditions (entity, location, stage) and cancer treatment (chemotherapy, radiotherapy, surgery), as well as other factors in individual patients. Important individual factors are, for example, sex, age at the time of treatment, and previous conditions, but also potentially the presence of a genetic predisposition [5] .
Known late effects include endocrine malfunction with growth retardation, thyroid conditions, and reduced fertility following ra-
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Cancer in children · Late effects · Long-term survival · Survivors' quality of life · Aftercare and transition Summary Today, 80% of children and adolescents with cancer survive their disease. From the results of aftercare research arises the question: Are the survivors also healthy? Many late effects depend on the type of cancer and its treatment. Patients with brain tumors and with malignant sarcomas are very often affected by secondary diseases. Data from the USA report that around 2/3 of all patients still living 30 years after their cancer treatment in childhood suffer from late complications. Equivalent figures for Germany were previously unavailable. In accordance with the guidelines, regular follow-ups to diagnose a relapse or possible late effects have mostly been carried out in the primary children's hospitals. In adolescence and in young adulthood, this regimen does no longer serve the patients' mental and physical needs. To ensure appropriate care for this maturing patient group, interdisciplinary approaches (e.g., aftercare consultations) are required in which pediatric oncologists collaborate with colleagues from the field of internal medicine and other disciplines. Individual, risk-adapted (depending on the cancer treatment) aftercare plans based on pre-existing aftercare recommendations must be drawn up for every patient and to secure the early diagnosis of possible late effects. The conservation of health and diotherapy and treatment with alkylating agents, cardiomyopathies from anthracyclines, hearing loss from platinum derivatives, reduction in renal function from ifosamide, neuropsychological and cognitive dysfunctions following cranial radiotherapy in combination with chemotherapy, and secondary malignancies following radiotherapy and topoisomerase II inhibitors, as well as posttraumatic stress disorder, fatigue, and reduced quality of life [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . To research this patient group, large-scale retrospective studies were carried out in the USA (Childhood Cancer Survivor Study, CCSS) and Great Britain (British Childhood Cancer Survivor Study, BCCSS) [16] . In Germany, the retrospective German Survivor Study, VIVE, is currently underway, with former patients between 25 and 45 years of age being surveyed for physical late effects, quality of life, fatigue, and sociodemographic factors.
Little study has been carried out on late effects that may present a long time after cancer. Following analyses of patient surveys (CCSS) in the USA, the incidences of late effects in comparison to the general population are noticeably increased [17] . The incidences of late complications associated with cancer and its associated treatment could be over 90% for those between 60 and 70 years of age ( fig. 1 ).
This data is supported by the St. Jude Lifetime Cohort Study, SJLIFE, including 1,713 long-term survivors at the St. Jude Children's Research Hospital, Memphis, USA, in which 95.2% of earlier cancer patients at the age of 45 have a chronic health problem [18] .
Take Home Message
The St Jude Lifetime Cohort Study (SJLIFE) in the USA reported a high percentage of late effects (> 95%) in adults after childhood cancer at the age of 45 [18] .
The 'Long-Term Observation' GPOH Committee
In Germany the 'long-term observation' GPOH (Association for Pediatric Oncology and Hematology) is currently coordinating all Late Effects aftercare groups. LESS (Late Effects Surveillance System), has been operational since 1989, formulating among other things risk-adapted aftercare recommendations for all GPOH therapy-optimizing studies. In addition, the aforementioned retrospective nationwide survey, VIVE, financed by Deutsche Krebs hilfe, is being carried out among 10,000 long-term survivors of childhood cancer, who are at the present time at least 25 years old and for whom at least 10 years have elapsed since therapy. Participating in this survey are the German Childhood Cancer Register, the Life Quality Working Group, the therapy study managers, and the Late Effects Working Group (LESS). These German groups are also connected to the EU-financed research projects, the PanCare Network (www.pancare.eu) and its 2 EU-funded projects PanCareSurFup (www.pancaresurfup.eu) and PanCareLIFE (www.pancarelife.eu) [19] .
Late effects from radiotherapy in childhood and adolescence are set out in the eponymous register, RiSK. It was initiated by the 'Pediatric Radio-Oncology Working Group' (APRO) in 1998 and sponsored over 10 years by the Deutsche Kinderkrebsstiftung (German Childhood Cancer Foundation). RiSK researches in various projects the correlation between radiation dose and irradiated volume as well as other patient and therapy parameters with various radiogenic toxicities. As a result, a suitable radiation plan will lead to lower late effects rates.
In the early years following the end of therapy, late effects and relapse aftercare are carried out in parallel, occurring in connection with the respective cancer condition and treatment following the GPOH aftercare plans (further reading at www.kinderkrebsinfo. de). With a focus on aftercare and long-term observation, the following long-term late effects prevail:
Metabolic [17] .
Later Late Effects 'Later late effects' only develop in certain cases when the former childhood cancer-suffers have grown up. Examples are:
Metabolic disorders -hormone disorders after CNS radiotherapy for brain tumor Secondary malignancies Heart diseases -cardiomyopathy Infertility -early-onset menopause Fatigue and posttraumatic stress disorder; adaptation disorders. Some important aspects of long-term aftercare include the follow-up of existing late effects such as cardiotoxicity, metabolic disorders, (in)fertility and the desire to have children, and secondary malignancies, but also occupational and social counselling. Patients in recovery from brain tumors and stem cell transplants are high-risk patients.
Why Long-Term Aftercare is so Important
After anthracycline therapy, dependent on the dose administered, the cumulative incidence of heart failure 30 years after the end of therapy is 7.5-10% ( fig. 2) . Consequently, selected somatic but also psychological late effects are included in and recommendations are made for the long-term follow-up of formerly cancersuffering children and adolescents.
Important 'Later Late Effects'
Second Primary Neoplasms Second primary neoplasms are secondary malignancies which are histologically distinct from the primary cancer. In the literature, the cumulative incidence after 30 years since onset and treatment is given as 5-30% [20] . The individual risk concerning the primary cancer condition is dependent, amongst others, on the therapy administered (chemo-and/or radiotherapy). Alkylating agents, such as cyclophosphamide, ifosfamide or busulfan, as well as topoisomerase II inhibitors, and also the anthracyclines are known risk factors for therapy-related leukemia. Solid tumors can in suspected cases appear as sequelae of radiotherapy and constitute around 80% of all second primary neoplasms [21, 22] . Risk factors include young age at the time of irradiation, treatment dosage, and the time interval following the end of treatment.
One example is breast cancer after mediastinal irradiation for patients with Hodgkin's disease. Following the analyses of the Life After Hodgkin's working group of Prof. Schellong and Dr. Dörffel [20] , 30 years from the end of therapy, every 5th woman who was irradiated during puberty in the breast area will develop breast cancer. For this reason, a cooperation was initiated with the German Consortium for Familial Breast and Ovarian Cancer (www.konsortium-familiaerer-brustkrebs.de). Female patients with Hodgkin's disease were included in a screening program [20] . Other malignancies described after treatment for Hodgkin's disease include thyroid carcinomas, pancreatic carcinomas, and mesotheliomas [23, 24] , so that raising awareness among patients and the offer of long-term aftercare for this patient cohort are necessary.
Causes and Early Diagnosis of Anthracycline-Induced Cardiomyopathy
The use of anthracyclines is restricted on grounds of cardiac toxicity which can present in 2 forms: The acute form appears during or shortly after the end of treatment, is dose-dependent, and presents in the form of reversible myo-or pericarditis or ventricular and supraventricular arrhythmias. In contrast, the chronic form manifests itself months or years after the end of treatment as heart failure from an early-onset or late-onset type of cardiomyopathy and can be traced back to irreversible damage to the myocardium. To the presently known clinical risk factors of anthracycline-induced cardiomyopathy can be added a high cumulative anthracycline dose, high single dosage or dosage intensity, short duration of application (bolus dose), pre-existing cardiac conditions, additional radiotherapy (especially in the thoracic area, mediastinum), very young age at the time of treatment, as well as a long period since therapy [25] . Notably, the incidence of severe heart failure rises steadily, even 30 years after the end of therapy, to 7.5-10% according to the anthracycline dose [26] (fig. 2) .
Metabolic Syndrome -Excessive Weight, High Blood Pressure, High Lipid Counts, Insulin Resistance
Adolescents who had childhood cancer can suffer from symptoms of a metabolic syndrome and are consequently at much higher risk of cardiovascular conditions and diabetes mellitus. The surveys carried out by the CCSS demonstrated a reduced level of physical activity among former patients [27] . Obesity is significantly higher among survivors of childhood cancer than among the general population. Even during treatment, altered eating habits and lack of physical activity were often the predictors of a later eating disorder or obesity [28] . Studies describe the following risk factors for elevated weight: restricted physical capacity, food with a clearly excessive calorific content and low intake of vitamins and Fig. 2 . After anthracycline therapy, dependent on the dose administered, the cumulative incidence of heart failure 30 years after cancer diagnosis is 7.5-10%. Modified according to [26] . trace elements, previous irradiation of the pituitary and hypothalamus areas [29] , changed activity in lipid metabolism (interrupted interplay between the adipokine leptins and adiponectins), and increased insulin resistance [30] .
Fatigue Syndrome
Many cancer patients suffer during, but also years after, an oncological treatment from a psychologically very stressful chronic fatigue syndrome (tumor-related fatigue syndrome). The subjective experience of persistent fatigue and severe exhaustion on the physical and psychological level bears no relation to the actual stress exposure, does not improve after periods of rest, and leads to a considerable reduction in quality of life. Adolescents also suffer from fatigue after oncological treatments in childhood. They are deemed to be physically 'healthy' and yet, on account of their fatigue, are considerably restricted and thereby often confronted with complete or partial unemployment -with the ensuing psychological, psycho-socially stigmatizing, financial, and (on the social level) economic implications. Within the post-Hodgkin's disease group of children and adolescents, fatigue syndrome is mostly found among young women [31] . Even the demarcation of fatigue syndrome from depressive illness is problematic. The treatment of cancer-related fatigue syndrome is currently based on behavioral therapeutic measures (time management, etc.) or the 'off-label' use of medicines for other neurological conditions (e.g., Parkinson's treatment) and is successful in only a very small percentage. It is therefore to be concluded that up to 30% of former cancer patients suffer from fatigue symptoms, such as tiredness, listlessness, weaknesses, loss of stamina, indifference, lack of motivation, sleep disorders, sadness, frustration or irritability, mental exhaustion, fearfulness, problems with concentration, loss of interest in life, and alienation from friends and family [32] .
Late Effects Diagnostics
In relation to the condition, the treatment, and the age, sex, and certain predispositions of the patient, GPOH risk-adapted aftercare plans have been developed. These can be found in the aftercare guidelines of the AWMF (Association of the Scientific Medical Societies in Germany) (www.awmf.org/leitlinien/detail/ll/025-003. html), on the patient information page of the GPOH (www. 
Transition from Childhood Oncology to Adult Medicine
When a former childhood cancer sufferer turns 18 and the end of his therapy lies more than 5-10 years ahead, this can lead to a handover from pediatric oncology centers to general practitioners/ internists. At this time, the patient may fall between the cracks if he/she finds no point of contact for adult aftercare. In Germany, there is a national framework for adolescent and young adult hematology and oncology and transition from pediatric to adult care addressing these issues (AjET working group) [33] .
A central institution within the GPOH network, which is able to contact a huge amount of former patients beyond their treatment phase, is the German Childhood Cancer Registry (GCCR) [34] . Currently, about 33,000 patients have expressed their willingness to be included in active long-term follow-up. The long-term follow-up includes regular contact by mail with each participating former patient (at least every 5 years) to ask about general health status, second primary neoplasms, relapses, and deaths. Patients report circumstances and late effects related to their former disease via a self-completing questionnaire. All reported second primary neoplasms are validated by contacting the treating physicians. Additionally, collaborative research projects like VIVE (see above) were conducted by using these follow-up structures.
What is missing are hospital-based structures to diagnose and validate all known forms of late effects on a (if necessary) lifelong basis. As there is currently no unifying regimen for the targeted transition of this patient group into adulthood-centered medicine, many patients continue to trust 'their Children's hospital' for as long as they can. Many attempt, with varying degrees of success, to organize their aftercare alone. The more complicated the background, including late effects, the more difficult is the search for an appropriate point of contact. To be entrusted with such patients demands not only medical knowledge and oncological experience, but also collaboration and coordination between different disciplines, such as endocrinology, nephrology, cardiology, orthopedics, gynecology, urology, and dermatology.
For childhood and adolescence cancer survivors, there are follow-up appointments at all pediatric cancer centers in Germany, Austria, and Switzerland. Currently in the process of being developed are long-term follow-up/late effects clinics for adults who suffered from cancer as children or adolescents. These should be performed on an interdisciplinary basis by a pediatric oncologist and an internist/general practitioner or similar. Networking should take place between local consultants at the clinic and other disciplines (according to indication) to ensure a seamless flow of information and an optimized aftercare. Ideally, in the context of routine aftercare, data on aftercare should be fed back to the GPOH studies and on this basis, defined research and aftercare projects be carried out, e.g., 'cardiovascular risk factors and metabolic syndrome with former cancer survivors' (aftercare research). A network of all these new long-term follow-up/late effects clinics for a unified approach would be desirable. In addition, appropriate follow-up appointments for (young) adults can be offered after cancer.
Practical Aims
The goal of structured and regular long-term observation of former pediatric cancer patients is to diagnose diseases and therapy-related late effects and, if necessary, offer treatment in collaboration with other disciplines, including experts in psychosocial and psychosomatic issues. Summing up the challenges that must be overcome here, recommendations for aftercare consultations should be matched using current late effects research as well as international cooperation regarding aftercare (www.ighg.org). It should be kept in mind that in the context of the transition into adulthood, change of doctors and moving to other locations can cause disruption. For the best aftercare of former childhood cancer patients, the patients and/or the parents (dependent on age) should be offered an aftercare passport at the end of treatment, along with an aftercare schedule and/or information about aftercare and late effects, using modern media/IT solutions. A so-called electronic 'Survivor Passport', containing important information on past treatments and illnesses of former patients, is in preparation Europe-wide under the aegis of the 'ENCCA' (European Network of Cancer Research in Children and Adolescents) EU Consortium.
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